Lisata Therapeutics (FRA:8NE) Cash-to-Debt : 252.41 (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Lisata Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lisata Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 252.41.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Lisata Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Lisata Therapeutics's Cash-to-Debt or its related term are showing as below:

FRA:8NE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.88 Med: 92.5 Max: No Debt
Current: 252.03

During the past 13 years, Lisata Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.88. And the median was 92.50.

FRA:8NE's Cash-to-Debt is ranked better than
83.66% of 1524 companies
in the Biotechnology industry
Industry Median: 6.225 vs FRA:8NE: 252.03

Lisata Therapeutics Cash-to-Debt Historical Data

The historical data trend for Lisata Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lisata Therapeutics Cash-to-Debt Chart

Lisata Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

25.70

55.40

132.99

142.68

300.92

Lisata Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															144.83	150.25	330.96	300.92	252.41

Competitive Comparison of Lisata Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Lisata Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lisata Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Cash-to-Debt falls into.

Lisata Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lisata Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	46.341	/	(0.154	+	0)
	=	300.92

Lisata Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	39.881	/	(0.158	+	0)
	=	252.41

Lisata Therapeutics (FRA:8NE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lisata Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lisata Therapeutics (FRA:8NE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (FRA:8NE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

LSTA:USA

Address

110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920

Website

https://www.lisata.com

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Lisata Therapeutics (FRA:8NE) Headlines

No Headlines